全文获取类型
收费全文 | 2619篇 |
免费 | 193篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 125篇 |
妇产科学 | 66篇 |
基础医学 | 369篇 |
口腔科学 | 80篇 |
临床医学 | 419篇 |
内科学 | 567篇 |
皮肤病学 | 48篇 |
神经病学 | 107篇 |
特种医学 | 346篇 |
外科学 | 217篇 |
综合类 | 58篇 |
一般理论 | 1篇 |
预防医学 | 185篇 |
眼科学 | 30篇 |
药学 | 146篇 |
1篇 | |
肿瘤学 | 128篇 |
出版年
2022年 | 15篇 |
2021年 | 26篇 |
2020年 | 17篇 |
2019年 | 40篇 |
2018年 | 39篇 |
2017年 | 32篇 |
2016年 | 42篇 |
2015年 | 37篇 |
2014年 | 41篇 |
2013年 | 77篇 |
2012年 | 93篇 |
2011年 | 83篇 |
2010年 | 76篇 |
2009年 | 83篇 |
2008年 | 94篇 |
2007年 | 104篇 |
2006年 | 81篇 |
2005年 | 72篇 |
2004年 | 68篇 |
2003年 | 77篇 |
2002年 | 69篇 |
2001年 | 82篇 |
2000年 | 74篇 |
1999年 | 64篇 |
1998年 | 107篇 |
1997年 | 100篇 |
1996年 | 121篇 |
1995年 | 94篇 |
1994年 | 95篇 |
1993年 | 82篇 |
1992年 | 52篇 |
1991年 | 64篇 |
1990年 | 50篇 |
1989年 | 62篇 |
1988年 | 60篇 |
1987年 | 46篇 |
1986年 | 54篇 |
1985年 | 53篇 |
1984年 | 29篇 |
1983年 | 41篇 |
1982年 | 30篇 |
1981年 | 33篇 |
1980年 | 26篇 |
1979年 | 27篇 |
1978年 | 20篇 |
1977年 | 24篇 |
1976年 | 22篇 |
1975年 | 15篇 |
1974年 | 20篇 |
1969年 | 14篇 |
排序方式: 共有2900条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Electrophysiologic effects of d-sotalol in humans 总被引:1,自引:0,他引:1
J M McComb B McGovern J B McGowan J N Ruskin H Garan 《Journal of the American College of Cardiology》1987,10(1):211-217
Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potential in humans, without affecting the upstroke velocity of depolarization. The dextrorotatory isomer, d-sotalol, retains these class III effects, but has little beta-blocking activity in vitro. d-Sotalol has not been studied extensively in humans. The electrocardiographic (ECG) and electrophysiologic effects of d- and d,l-sotalol were therefore assessed in a prospective randomized study of 20 patients. Each patient received either d-sotalol (1, 1.5 or 2 mg/kg body weight) or d,l-sotalol (1 mg/kg) by intravenous infusion. The QT and QTc intervals were prolonged and refractoriness increased in the atrium, atrioventricular (AV) node, His-Purkinje system and right ventricle after both d- and d,l-sotalol. After d-sotalol, the increases in both QT and QTc intervals and in atrial and ventricular effective refractory periods were dose dependent. Highly significant linear correlation was demonstrated between the plasma sotalol level and the change in QT (r = 0.86, p = 0.001) and QTc intervals (r = 0.79, p = 0.002), and between the plasma sotalol level and the effective refractory period of the right atrium (r = 0.75, p = 0.005) and ventricle (r = 0.70, p = 0.025). This study confirms that d-sotalol has effects consistent with class III properties. It demonstrates these effects in humans, and suggests that d-sotalol may prove to be a useful antiarrhythmic agent. 相似文献
5.
6.
7.
8.
OBJECTIVE: The aim of this study was to assess the severity of epilepsy and
its effect on patients lives, and to describe patients' use of and
attitudes to health care. METHOD: A questionnaire was sent to 595 people
with epilepsy identified from 14 general practices in north-west Bristol.
All patients aged 16 years and over receiving anti-epileptic medication for
their epilepsy were included in the study. Areas investigated included
severity of epilepsy and its effect on quality of life, anti-epileptic
medication and its perceived effect, health care utilization and
preferences for health care. RESULTS: Seizure frequency was strongly
associated with adverse effects of epilepsy. Attacks of epilepsy were
experienced at least monthly by 20.4% (95% confidence intervals (Cl)
17.0-23.7%) of patients, 29.4% (25.4-33.4%) took more than one
anti-epileptic drug, 56.1% (50.1-62.2%) reported drug side effects, 74.1%
(70.3-77.8%) would prefer to receive all or most of their epilepsy care in
a general practice setting, and 69.8% (63.5- 76.2%) would like contact with
a primary care-based epilepsy specialist nurse. During the previous year
42.4% (35.9-48.8%) of patients had not seen a doctor about their epilepsy.
Of patients who had attended the general practice only 13.4% (9.6-17.2%)
had regular arrangements to see their GP about epilepsy. Patients receiving
both primary and secondary care had the greatest needs and wants for
improved care. CONCLUSIONS: Structured care, including regular
appointments, co-ordination of primary and secondary care, and increased
monitoring and discussion, may improve the quality of life of people with
epilepsy, but requires evaluation.
相似文献
9.
10.
Y Leskinen JP Salenius T Lehtim?ki H Huhtala H Saha 《American journal of kidney diseases》2002,40(3):472-479
BACKGROUND: Knowledge of the prevalence of peripheral arterial disease (PAD) in patients with chronic renal failure (CRF) is limited because of a lack of uniformity in disease definition and recognition. Furthermore, little is known of the prevalence of medial arterial calcification (MAC) in patients with CRF. Our goal is to study the prevalence of PAD and MAC defined by ankle brachial index (ABI) or toe brachial index (TBI) measurements in a Finnish population of patients with CRF consisting of predialysis and dialysis patients, as well as renal transplant recipients. METHODS: We examined 136 patients with CRF and 59 control subjects. Fifty-nine of the patients with CRF had moderate to severe predialysis CRF, 36 patients were on dialysis treatment, and 41 were renal transplant recipients. Mean age of patients was 51.9 +/- 11.5 years, and 39 patients (29%) had diabetes. ABI and TBI were measured by means of photoplethysmography. The definition of PAD required an ABI value of 0.90 or less, a TBI value of 0.60 or less, or a previous positive lower-extremity angiogram result. ABI values of 1.3 or greater or incompressible arteries at ankle level indicated MAC. The presence of claudication was determined by an interview. RESULTS: Prevalences of PAD on this study were 22.0% in patients with predialysis CRF, 30.6% in patients on dialysis treatment, 14.6% in renal transplant recipients, and 1.7% in the control group (P = 0.001). Prevalences of MAC were 23.7%, 41.7%, 23.1%, and 3.4% (P < 0.001), respectively. Only 9 patients had claudication, and 6 of those patients had PAD. CONCLUSION: Both asymptomatic PAD and MAC are common in patients with CRF. Therefore, we recommend the use of both ABI and TBI measurements in the evaluation of PAD in patients with CRF. 相似文献